The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets

Home >
Life Sciences >
Pharmaceutical >
The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets

Report price : $ 3 995
Publication date : October 2009

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets

At their most basic level, wellness programs represent an attempt to encourage good health and thereby decrease utilization of health care products and services. They have evolved out of necessity from the current U.S. health care system, in response to a variety of factors including continually rising costs of care and declining quality of life.

A Comprehensive Look at the 'Wellness' Industry

Utilization of wellness programs in the United States has experienced strong recent growth this is expected to continue through the forecast period. As more people participate in wellness programs, their usage of various health care products and services will be affected, as well the revenues of wellness program providers.
This report looks at the emerging wellness industry and estimates the market for wellness related products and services. This portion of the report examines:

Drivers of Wellness Services

Utilization Statistics

Major Companies and Offerings

Current Wellness Program Market Size

Innovative Approaches

Results of Programs

General Trends (Weak U.S. Economy, Postponing of Retirement, EMR, Rising Interest in Anti-Aging)

Industry Trends (Internet-Based Wellness Programs, Usage of Financial Incentives, Emergence of Retail Clinics)

A Report No Pharmaceutical, Device or Testing Product Marketer Should Be Without

If wellness programs are effective, there should be an impact on all healthcare industries: pharmaceuticals, devices and diagnostics. Positive impact for some, negative for others. As part of Kalorama's unique analysis on this topic, this report also takes a look at how the popularity of wellness programs will effect other markets. The report estimates the positive or negative sales impact of wellness programs upon established U.S. markets for various health care products and services including:

Allergy Medicines

Cholesterol Reducers

Diabetes Drugs

Gastrointestinal Medications/Proton Pump Inhibitors

Hypertension Medicines

Over-the-Counter (OTC) Medicines

Influenza Vaccines

Cervical Cancer Vaccines

Diagnostic Tests

Cardiovascular, Gastric Banding, and other Devices

Surgeries,

Imaging

Other Medical Services

Within each of these market segments, products, services and/or sub-segments were selected that will particularly be affected by wellness programs. Products, services and/or sub-segments that are not expected to be significantly impacted were not included.

Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are provided for the historic 2004 - 2008 period and forecasts are provided through 2013. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

Because this industry is extremely fragmented, with thousands of providers offering many different types of programs tailored to different patient populations, an effort was made to include a broad representation of groups. Companies profiled include:

Aetna

Azente Wellness

Cigna

Coleman Wellness Solutions

ConnectiCare

Corporate Wellness

ConvergenceHealth

CuraLinc Healthcare

Dynamic Wellness

Employee Health Management Systems

Hawaii Medical Assurance Association

incentaHEALTH

KC Wellness

Kersh Risk Management.

Kronos Optimal Health Company

Mayo Clinic Health Solutions

MedHealth Solutions

MO Healthnet

Multicare Health System

National Corporate Wellness.

Nuvita

PATH

Physicians Medical Group of Santa Cruz County

Preventure

Professional Health Services

Pure Wellness

Summit Health..

San Francisco Wellness Initiative

US Corporate Wellness

Wellness Advantage

Wellness Corporate Solutions

Wellness Works

Wyoming State Wellness Program

CHAPTER ONE: EXECUTIVE SUMMARY: Wellness Programs And Their Impact on U.S. Healthcare Markets; Scope and Methodology; Introduction; Key Healthcare Markets Impacted by Wellness Programs; Wellness Programs market
CHAPTER TWO: INTRODUCTION: The U.S. Health Care System Today; Costs Related To A Lack Of Wellness; Wellness Programs
CHAPTER THREE: KEY HEALTH CARE MARKETS IMPACTED BY WELLNESS PROGRAMS: Prescription Medicines; Non-Prescription Medicines; Adult Vaccines; Clinical Diagnostic Tests; Medical Devices; Medical Services; Total Effects of Wellness Programs
CHAPTER FOUR: WELLNESS PROGRAMS MARKET: Program Provider Revenues; Issues and Trends; Weak U.S. Economy; Postponing of Retirement; Internet-Based Wellness Programs; Usage of Financial Incentives; Electronic Medical Records; Declining Public Health; Pressure to Democratize Wellness; Rising Interest in Anti-Aging; Emergence of Retail Clinics
CHAPTER FIVE: PROVIDER PROFILES: Aetna; Azente Wellness; Cigna; Coleman Wellness Solutions; ConnectiCare; Corporate Wellness; ConvergenceHealth; CuraLinc Healthcare; Dynamic Wellness; Employee Health Management Systems; Hawaii Medical Assurance Association; incentaHEALTH; Infinite Wellness Solutions; KC Wellness; Kersh Risk Management; Kronos Optimal Health Company; Mayo Clinic Health Solutions; MedHealth Solutions; MO Healthnet; Multicare Health System; National Corporate Wellness; Nuvita; PATH; Physicians Medical Group of Santa Cruz County; Preventure; Professional Health Services; Pure Wellness; San Francisco Wellness Initiative; Summit Health; US Corporate Wellness; Wellness Advantage; Wellness Corporate Solutions; Wellness Works
TABLE OF EXHIBITS
CHAPTER TWO: INTRODUCTION: Figure 2-1: National Health Expenditures (NHE) and NHE as a Percent of GDP, 1980-2017; Figure 2-2: Premium Increases vs. Increases in Workers Earnings and Prices, 1989-2008; Figure 2-3: Consumer Out of Pocket Expenditures per Worker, 2003-2013; Figure 2-3: Unnecessary Deaths Resulting From Variations in Health Care Quality, 2008; Table 2-1: U.S. Health Care Coverage by State, 2009; Figure 2-4: U.S. Costs for Illness Treatment and Prevention, 1980-2017; Table 2-2: Obesity in the United States, 1980-2013; Table 2-3: Common Diseases of the Lungs, 2009
CHAPTER THREE KEY HEALTH CARE MARKETS IMPACTED BY WELLNESS PROGRAMS: Table 3-1: Effect of Wellness Programs on Key U.S. Health care Markets; Table 3-2: U.S. Rx Allergy Drug Sales and Impact of Wellness Programs, 2004 -2013; Table 3-3: Types of Cholesterol Reducing Medications and Their Effect; Table 3-4: U.S. Rx Cholesterol Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-5: U.S. Diabetes Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-6: U.S. Rx Gastrointestinal/PPI Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-7: U.S. Rx Hypertension Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-8: Total U.S. Rx Drug Sales and Impact of Wellness Programs on Selected Drug Groups, 2004-2013; Figure 3-1: Impact of Wellness Programs on Selected Rx Drug Groups, 2004-2013; Table 3-9: U.S. OTC Allergy Remedy Sales and Impact of Wellness Programs, 2004-2013; Table 3-10: U.S. Blood Glucose Testing Sales and Impact of Wellness Programs, 2004-2013; Table 3-11: U.S. OTC Gastrointestinal Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-12: U.S. OTC Smoking Cessation Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-13: U.S. OTC Weight Loss Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-14: Total U.S. OTC Drug Sales and Impact of Wellness Programs on Selected Drug Groups, 2004-2013; Figure 3-2: Impact of Wellness Programs on Selected OTC Drug Groups, 2004-2013; Table 3-15: U.S. Influenza Vaccine Sales and Impact of Wellness Progress 2004-2013; Table 3-16: U.S. Cervical Cancer Vaccine Sales and Impact of Wellness Programs, 2004-2013; Table 3-17: U.S. Vaccine Sales and Impact of Wellness Programs, 2004-2013; Figure 3-3: Impact of Wellness Programs on Vaccine Sales, 2004-2013; Table 3-18: U.S. POC Test Sales and Impact of Wellness Programs, 2004-2013; Table 3-19: U.S. Clinical Chemistry and Immunoassay Test Sales and Impact of Wellness Programs, 2004-2013; Table 3-20: U.S. Clinical Test Sales and Impact of Wellness Programs, 2004-2013; Figure 3-4: Impact of Wellness Programs on Clinical Diagnostic Tests, 2004-2013; Table 3-21: U.S. Cardiovascular Device Sales and Impact of Wellness Programs on Selected Drug Groups, 2004-2013; Table 3-22: U.S. Gastric Banding Device Sales and Impact of Wellness Programs, 2004-2013; Table 3-23: Selected U.S. Medical Device Sales and Impact of Wellness Programs, 2004-2013; Figure 3-5: Impact of Wellness Programs on Medical Devices, 2004-2013; Table 3-24: U.S. Surgical Intervention Revenues and Impact of Wellness Programs, 2004-2013; Table 3-25: U.S. Medical Imaging Revenues and Impact of Wellness Programs, 2004-2013; Table 3-26: Selected U.S. Medical Service Revenues and Impact of Wellness Programs, 2004-2013; Figure 3-6: Impact of Wellness Programs on Medical Services, 2004-2013; Table 3-27: Total U.S. Health Care Market Revenues, 2004-2013,; Figure 3-7: Total U.S. Health Care Market, by Segment, 2008; Figure 3-8: Total U.S. Health Care Market, by Segment, 2013; Table 3-28: U.S. Health Care Revenues Lost or Gained from Wellness Programs, 2004-2013; Figure 3-9: U.S. Health Care Revenues Lost or Gained from Wellness Programs, by Segment, 2004-2013; Figure 3-10: Total Effect on U.S. Health Care Revenues Lost or Gained from Wellness Programs, by Segment, 2004 - 2013; Table 3-29: Growth of Total U.S. Health Care Revenues and Revenues Lost or Gained from Wellness Programs, 2004-2013; Figure 3-11: Annual U.S. Health Care Industry Growth vs. Growth of Lost or Gained Revenues from Wellness Programs, by Segment, 2004-2008; Figure 3-12: Annual U.S. Health Care Industry Growth vs. Growth of Lost or Gained Revenues from Wellness Programs, by Segment, 2008-2013
CHAPTER FOUR: WELLNESS PROGRAMS MARKET: Table 4-1: U.S. Wellness Programs Market, 2004-2013; Figure 4-1: U.S. Spending on Wellness Programs as a Proportion of Total Spending on Health Care Prevention, 2004-2013; Table 4-2: Effect on Wellness Programs of Industry Trends
CHAPTER FIVE: PROVIDER PROFILES: Table 5-1: Aetna’s Revnue and Net Earnings, 2006-2008; Table 5-2: Cigna’s Revnue and Net Earnings, 2006-2008

RELATED REPORTS

Boosting Immunity Through Digestion: The Relation Among Probiotics, Prebiotics and Digestive Enzymes

$ 3 850
October 2009

Probiotic literally means “for life.” The Joint Food and Agriculture Organization/World Health Organization defines probiotics as “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.” Prebiotics are nondigestible carbohydrates that feed be ...

Industries : Pharmaceutical

Pharmaceutical and healthcare market in Poland 2009

$ 3 666
June 2009

The report comprises the complete economic analysis of pharmaceutical sector in Poland as well as recent data on healthcare sector in the region and contains forecast projections for 2009-2011.The value data are presented for the total market, pharmacy and hospital segment, Rx, foreign and domestic ...

Industries : Pharmaceutical, Healthcare

Digestive Remedies in Venezuela

$ 898
August 2009

Euromonitor International's Digestive Remedies in Venezuela report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowing you to identify the sectors driving growth. It identifies the leading companies, the ...

Industries : Pharmaceutical

Digestive Remedies in Slovakia

$ 898
July 2009

Euromonitor International's Digestive Remedies in Slovakia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowing you to identify the sectors driving growth. It identifies the leading companies, the ...

Industries : Pharmaceutical

Digestive Remedies in Morocco

$ 898
August 2009

Euromonitor International's Digestive Remedies in Morocco report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowing you to identify the sectors driving growth. It identifies the leading companies, the l ...

Industries : Pharmaceutical

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

$ 3 500
October 2009

The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types ...

Industries : Pharmaceutical

Reinventing Pharmaceutical Sales Forces

$ 7 695
April 2009

Frustrated customer groups and leaner economic times have forceda new pharmaceutical sales model to emerge. The arms race of theprevious decade is dead. Faced with the challenge of increasingreach despite sales force cuts, companies are turning toward buildingstronger, more personal rep-physician re ...

Industries : Pharmaceutical

Thought Leader Fair-Market Value: Compensation Benchmarks and Procedures

$ 7 695
January 2009

Thought Leader FMV: Compensation and ProceduresThought leader management teams face many new challenges in today’s environment. Academic institutions have implemented new regulations limiting or, in some cases, forbidding their faculty’s relationships with drug manufacturers. Individual ...

Industries : Pharmaceutical

Driving Successful Pharma Brands: Case Studies of Real Product Launches

$ 7 695
January 2009

Make all the right spending choices at the right time — and maximize product sales performance. Driving Successful Pharma Brands:Case Studies of Real Product Launches delivers original analysisand real, phase-by-phase marketing budgets for 13 US brands of allsizes, representing various therape ...

Industries : Pharmaceutical

Competitor Analysis: Plk-1 Inhibitors

$ 125
May 2009

Product description The present Competitive Intelligence Report about Plk-1 Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting the polo-like kinase 1 for treatment of cancer as of May 2009. Polo-like kinase (Plk) is an important cell cycle regulatory kinas ...

Industries : Pharmaceutical

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets - get our PDF brochure

24/7 Customer Service

Contact Shadi now !

(866) 682 9815
Ask Shadi by email

Related industries

Pharmaceutical Industry

Related companies

Program Productions

More companies

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.